CPMV
Mosaic ImmunoEngineering, Inc.
Set alert
- YTD
- -55.95%
- 1 year
- -83.65%
- Open
- 0.06
- Prev close
- 0.137
- Mkt cap
- 992.17K
- Vol
- 2
- Avg vol
- 610
- EPS
- -0.10
- P/E
- 0.00
More statistics
- Low
- 0.06
- High
- 0.06
- Earnings
- Nov 2, 2023
News
2 weeks ago defenseworld.net
Mosaic ImmunoEngineering (OTCMKTS:CPMV) Stock Jumps 432.8% – Here’s Why
Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV - Get Free Report)'s stock price rose 432.8% during mid-day trading on Friday. The company traded as high as $0.3330 and last traded at $0.3330.…
6 months ago defenseworld.net
Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Update
Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totaling…
2 years ago accesswire.com
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy…
5 years ago accesswire.com
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
- Nanoparticle-based technology complements the company's intratumoral technology platform - NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"),…
5 years ago accesswire.com
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and…
5 years ago accesswire.com
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly…
5 years ago accesswire.com
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that…
5 years ago accesswire.com
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine…
5 years ago accesswire.com
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101
- Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with…
5 years ago accesswire.com
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and…